Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer

Objective. To investigate the clinical value of lentinan combined with (125)I brachytherapy in the treatment of recurrent ovarian cancer. Methods. A total of 160 patients with recurrent ovarian cancer admitted at Jiaozhou Central Hospital from June 2009 to October 2015 were enrolled in this study an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qin Jiang, Shuai Pang, Yifang Xia, Hongmei Sun, Yingying Yu
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Other systems of medicine RZ201-999
Acceso en línea:	https://doaj.org/article/3ec21415ad0f426cafe3ae2c482a54b5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3ec21415ad0f426cafe3ae2c482a54b5
record_format	dspace
spelling	oai:doaj.org-article:3ec21415ad0f426cafe3ae2c482a54b52021-11-22T01:09:52ZLentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer1741-428810.1155/2021/2472444https://doaj.org/article/3ec21415ad0f426cafe3ae2c482a54b52021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/2472444https://doaj.org/toc/1741-4288Objective. To investigate the clinical value of lentinan combined with (125)I brachytherapy in the treatment of recurrent ovarian cancer. Methods. A total of 160 patients with recurrent ovarian cancer admitted at Jiaozhou Central Hospital from June 2009 to October 2015 were enrolled in this study and randomly divided into observation group (80 cases) and control group (80 cases). The control group received chemotherapy. Observation group (80 cases) was treated with lentinan combined with (125)I brachytherapy on the basis of control group, and the efficacy, adverse reactions, and Karnofsky Performance Scale (KPS) and quality of life scale (QOL) scores of the two groups were analyzed and compared. Results. After treatment, the levels of CA125, CA199, and CA724 in the 2 groups were markedly lower than those before treatment, and the observation group was lower than the control group (P<0.05). After treatment, the proportion of CD4+/CD8+ cells and helper T cells and NK cells in the control group remarkably depleted, while the proportion of CD4+/CD8+ cells, NK cells, and B cells in the observation group increased significantly compared to that before treatment, and the level of IgA, IgG, and IgM in the control group decreased, while that in the observation group showed no conspicuous difference compared with that before chemotherapy (P>0.05). The effective rate of observation group (85%) was higher than that of control group (75%) (P<0.05). The overall survival of patients in the control group was (16.2 ± 2.04) months and that of the observation group was (24.8 ± 1.8) months. KPS and QOL scores in both groups were enormously higher than those before treatment, and the observation group was higher than the control group (P<0.05). The incidence of hemoglobin reduction, leukopenia, aglobulia, granulocytopenia, nausea and vomiting, hepatorenal toxicity, and neurovirulence in the observation group was significantly lower than that in the control group. Conclusion. Lentinan combined with (125)I brachytherapy is effective in treating recurrent ovarian cancer, with mild adverse reactions and good tolerance.Qin JiangShuai PangYifang XiaHongmei SunYingying YuHindawi LimitedarticleOther systems of medicineRZ201-999ENEvidence-Based Complementary and Alternative Medicine, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Other systems of medicine RZ201-999
spellingShingle	Other systems of medicine RZ201-999 Qin Jiang Shuai Pang Yifang Xia Hongmei Sun Yingying Yu Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
description	Objective. To investigate the clinical value of lentinan combined with (125)I brachytherapy in the treatment of recurrent ovarian cancer. Methods. A total of 160 patients with recurrent ovarian cancer admitted at Jiaozhou Central Hospital from June 2009 to October 2015 were enrolled in this study and randomly divided into observation group (80 cases) and control group (80 cases). The control group received chemotherapy. Observation group (80 cases) was treated with lentinan combined with (125)I brachytherapy on the basis of control group, and the efficacy, adverse reactions, and Karnofsky Performance Scale (KPS) and quality of life scale (QOL) scores of the two groups were analyzed and compared. Results. After treatment, the levels of CA125, CA199, and CA724 in the 2 groups were markedly lower than those before treatment, and the observation group was lower than the control group (P<0.05). After treatment, the proportion of CD4+/CD8+ cells and helper T cells and NK cells in the control group remarkably depleted, while the proportion of CD4+/CD8+ cells, NK cells, and B cells in the observation group increased significantly compared to that before treatment, and the level of IgA, IgG, and IgM in the control group decreased, while that in the observation group showed no conspicuous difference compared with that before chemotherapy (P>0.05). The effective rate of observation group (85%) was higher than that of control group (75%) (P<0.05). The overall survival of patients in the control group was (16.2 ± 2.04) months and that of the observation group was (24.8 ± 1.8) months. KPS and QOL scores in both groups were enormously higher than those before treatment, and the observation group was higher than the control group (P<0.05). The incidence of hemoglobin reduction, leukopenia, aglobulia, granulocytopenia, nausea and vomiting, hepatorenal toxicity, and neurovirulence in the observation group was significantly lower than that in the control group. Conclusion. Lentinan combined with (125)I brachytherapy is effective in treating recurrent ovarian cancer, with mild adverse reactions and good tolerance.
format	article
author	Qin Jiang Shuai Pang Yifang Xia Hongmei Sun Yingying Yu
author_facet	Qin Jiang Shuai Pang Yifang Xia Hongmei Sun Yingying Yu
author_sort	Qin Jiang
title	Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
title_short	Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
title_full	Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
title_fullStr	Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
title_full_unstemmed	Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
title_sort	lentinan combined with (125)i brachytherapy for recurrent ovarian cancer
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/3ec21415ad0f426cafe3ae2c482a54b5
work_keys_str_mv	AT qinjiang lentinancombinedwith125ibrachytherapyforrecurrentovariancancer AT shuaipang lentinancombinedwith125ibrachytherapyforrecurrentovariancancer AT yifangxia lentinancombinedwith125ibrachytherapyforrecurrentovariancancer AT hongmeisun lentinancombinedwith125ibrachytherapyforrecurrentovariancancer AT yingyingyu lentinancombinedwith125ibrachytherapyforrecurrentovariancancer
_version_	1718418394178387968

Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer

Ejemplares similares